Logo image of RKV.CA

RAKOVINA THERAPEUTICS INC (RKV.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:RKV - CA75103L3092 - Common Stock

0.1 CAD
+0.01 (+5.26%)
Last: 1/2/2026, 7:00:00 PM
Fundamental Rating

0

Overall RKV gets a fundamental rating of 0 out of 10. We evaluated RKV against 0 industry peers in the Unkown industry. RKV has a bad profitability rating. Also its financial health evaluation is rather negative. RKV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RKV had negative earnings in the past year.
In the past year RKV has reported a negative cash flow from operations.
RKV had negative earnings in each of the past 5 years.
In the past 5 years RKV always reported negative operating cash flow.
RKV.CA Yearly Net Income VS EBIT VS OCF VS FCFRKV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

Industry RankSector Rank
ROA -158.75%
ROE -443%
ROIC N/A
ROA(3y)-53.87%
ROA(5y)-49.76%
ROE(3y)-70.85%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
RKV.CA Yearly ROA, ROE, ROICRKV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

RKV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RKV.CA Yearly Profit, Operating, Gross MarginsRKV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, RKV has more shares outstanding
The number of shares outstanding for RKV has been increased compared to 5 years ago.
The debt/assets ratio for RKV has been reduced compared to a year ago.
RKV.CA Yearly Shares OutstandingRKV.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
RKV.CA Yearly Total Debt VS Total AssetsRKV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -10.52, we must say that RKV is in the distress zone and has some risk of bankruptcy.
RKV has a Debt/Equity ratio of 0.61. This is a neutral value indicating RKV is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z -10.52
ROIC/WACCN/A
WACCN/A
RKV.CA Yearly LT Debt VS Equity VS FCFRKV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M 6M 8M

2.3 Liquidity

A Current Ratio of 0.78 indicates that RKV may have some problems paying its short term obligations.
A Quick Ratio of 0.78 indicates that RKV may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.78
RKV.CA Yearly Current Assets VS Current LiabilitesRKV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

RKV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.77%.
EPS 1Y (TTM)-34.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RKV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKV.CA Price Earnings VS Forward Price EarningsRKV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKV.CA Per share dataRKV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RKV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

RAKOVINA THERAPEUTICS INC

TSX-V:RKV (1/2/2026, 7:00:00 PM)

0.1

+0.01 (+5.26%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-28 2025-11-28
Earnings (Next)04-29 2026-04-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.51%
Ins Owner ChangeN/A
Market Cap2.12M
Revenue(TTM)N/A
Net Income(TTM)-8.36M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.12
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.09
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.75%
ROE -443%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.87%
ROA(5y)-49.76%
ROE(3y)-70.85%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.78
Altman-Z -10.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-264.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-264.92%
OCF growth 3YN/A
OCF growth 5YN/A

RAKOVINA THERAPEUTICS INC / RKV.CA FAQ

Can you provide the ChartMill fundamental rating for RAKOVINA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 0 / 10 to RKV.CA.


Can you provide the valuation status for RAKOVINA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to RAKOVINA THERAPEUTICS INC (RKV.CA). This can be considered as Overvalued.


How profitable is RAKOVINA THERAPEUTICS INC (RKV.CA) stock?

RAKOVINA THERAPEUTICS INC (RKV.CA) has a profitability rating of 0 / 10.


What is the financial health of RAKOVINA THERAPEUTICS INC (RKV.CA) stock?

The financial health rating of RAKOVINA THERAPEUTICS INC (RKV.CA) is 1 / 10.